Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, KalVista Pharmaceuticals Inc (NASDAQ: KALV) closed at $13.36 up 1.98% from its previous closing price of $13.1. In other words, the price has increased by $1.98 from its previous closing price. On the day, 1.24 million shares were traded. KALV stock price reached its highest trading level at $13.71 during the session, while it also had its lowest trading level at $13.06.
Ratios:
For a deeper understanding of KalVista Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.22. In the meantime, Its Debt-to-Equity ratio is 16.62 whereas as Long-Term Debt/Eq ratio is at 16.34.
Upgrades & Downgrades
In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19.
On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30.
On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 18 ’25 when Palleiko Benjamin L sold 4,466 shares for $14.48 per share. The transaction valued at 64,665 led to the insider holds 403,879 shares of the business.
Yea Christopher sold 2,683 shares of KALV for $38,848 on Nov 18 ’25. The CHIEF DEVELOPMENT OFFICER now owns 133,574 shares after completing the transaction at $14.48 per share. On Nov 18 ’25, another insider, Audhya Paul K., who serves as the CHIEF MEDICAL OFFICER of the company, sold 3,075 shares for $14.48 each. As a result, the insider received 44,524 and left with 125,877 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 675298432 and an Enterprise Value of 648719488. For the stock, the TTM Price-to-Sale (P/S) ratio is 472.24 while its Price-to-Book (P/B) ratio in mrq is 39.72. Its current Enterprise Value per Revenue stands at 454.922 whereas that against EBITDA is -3.214.
Stock Price History:
The Beta on a monthly basis for KALV is -0.18, which has changed by 0.3126253 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $17.28, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is 11.05%, while the 200-Day Moving Average is calculated to be 7.00%.
Shares Statistics:
For the past three months, KALV has traded an average of 1.28M shares per day and 1802740 over the past ten days. A total of 50.54M shares are outstanding, with a floating share count of 37.90M. Insiders hold about 25.03% of the company’s shares, while institutions hold 97.75% stake in the company. Shares short for KALV as of 1761868800 were 13328249 with a Short Ratio of 10.43, compared to 1759190400 on 12704464. Therefore, it implies a Short% of Shares Outstanding of 13328249 and a Short% of Float of 29.67.
Earnings Estimates
At present, 6 analysts are actively evaluating the performance of KalVista Pharmaceuticals Inc (KALV) in the stock market.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.43 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$1.65 and -$3.76 for the fiscal current year, implying an average EPS of -$3.03. EPS for the following year is -$2.0, with 7.0 analysts recommending between -$0.44 and -$2.59.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $28.33M. There is a high estimate of $39M for the next quarter, whereas the lowest estimate is $15.5M.
Based on 8 analysts’ estimates, the company’s revenue will be $119.54M in the next fiscal year. The high estimate is $242.2M and the low estimate is $33.71M.
